ALK and non-small cell lung carcinoma: The PROLUNG comparing pembrolizumab plus docetaxel versus docetaxel alone in pretreated NSCLC patients involved 25 patients with EGFR/anaplastic lymphoma kinase (ALK) alteration and found that the combination immunotherapy improved the objective response rate (ORR) and progress-free survival (PFS) in patients with EGFR variation (14).